Introduction
============

Colorectal cancer (CRC) is one of the most common malignant tumors with the third highest morbidity rate and the second highest mortality rate among males and females combined in the United States[@B1]. In China, CRC is the fifth most commonly diagnosed tumor, and the mortality rate of CRC has increased in recent years due to changes in lifestyle[@B2], [@B3]. Despite great advances in surgery and drug therapy, the five-year relative survival rate is only 65%, ranging from 90% to 14% in different stages[@B4]. The prognosis of CRC is affected by many factors, such as the quality of surgery, patients\' compliance, and adjuvant therapy. After curative surgery, postoperative pathological reports are usually the main references to predict the prognosis. In addition, preoperative serum tumor markers are classic and important components with referenced value.

The detection of preoperative tumor markers is widely used in clinical practice because of its great convenience and acceptability. Serum carcinoembryonic antigen (CEA) has always been at a core position as a reliable tumor marker in CRC, which is recommended by the NCCN guidelines as a prognostic and monitoring indicator. CEA is an acid glycoprotein involved in cell recognition and cell adhesion and is secreted by solid tumors. The level of preoperative CEA influences the prognosis of multiple tumors, such as gastric cancer, lung cancer and CRC[@B5], [@B6], [@B7]. Furthermore, CEA levels are correlated with the metastasis and recurrence of CRC after curative surgery[@B8], [@B9]. CA19-9 can be elevated in digestive system tumors. For CRC, the preoperative increased level of CA19-9 predicts poor survival of CRC, and postoperative CA19-9 is a valuable prognostic index for monitoring lung and liver metastasis[@B10], [@B11], [@B12]. CA125 is shown to be expressed in ovarian cancer and gynecological diseases[@B13]. Furthermore, CA125 is also an independent factor for the prognosis of CRC[@B14]. CA242 has high specificity and sensitivity in CRC. CA242 is expressed independently of CEA, and the combination of CEA and CA242 has more sensitivity in CRC than either alone[@B15].

Overall, many studies have confirmed the significance of serum tumor markers in the prognosis of CRC. However, few studies have focused on the elevated numbers of preoperative serum tumor markers in CRC. Therefore, in this study, the relation between preoperative tumor markers and clinicopathological characteristics was analyzed. We also investigated the effect of increased numbers of tumor markers on the prognosis of stage II and III CRC.

Materials and Methods
=====================

Patients
--------

This study was a single-center retrospective clinical study and was registered in the Chinese Clinical Trial Registry (Approval No. ChiCTR1800016906). The studies on human subjects were approved by the ethics committee of Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital (Approval No. 2018-KY-031K). Patients with pathologically diagnosed stage II and III CRC who underwent curative resection at the Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People\'s Hospital were selected for participation from January 2009 to October 2015. Written informed consents were gained from all patients in this study. Patients under age 18 and those with emergency operations, incompatible pathological types, multiple primary tumors, unclear causes of death or death within 30 days, or incomplete data as well as those who were lost to follow-up were excluded.

Data collection and outcome definition
--------------------------------------

The clinical characteristics of the patients, including gender, age, tumor location and pathological reports, were obtained from electronic patient records and the departmental database. Pathological stage was assessed according to the 8th AJCC criterion for CRC. The results of four preoperative tumor markers (CEA, CA125, CA19-9 and CA242) were collected from biochemistry reports of the Laboratory Medicine Department, and no patients received any adjuvant radiotherapy or chemotherapy before these four tumor markers were determined. The upper normal limits of CEA, CA125, CA19-9 and CA242 were 5 ng/ml, 15 U/ml, 27 U/ml and 15 U/ml, respectively. If the values of these tumor markers were above the upper limit, they were considered positive. To analyze the effect of the numbers of increased preoperative tumor markers on the prognosis of stage II and III CRC, the weight of each marker was first evaluated. Subsequently, the patients were scored as 0, 1, 2, 3 and 4 according to the positive numbers of tumor markers; thus, there were five groups in this study.

Follow-up
---------

All patients were followed up according to current guidelines, including blood laboratory testing, physical examination, colonoscopy, chest X-ray and CT (or MRI). The deadline for follow-up was October 31, 2017. Survival status and metastasis status were updated by telephone, email and medical history. Disease-free survival (DFS) was defined as the time from surgery to tumor metastasis or recurrence. Overall survival (OS) was defined as the time from surgery to death.

Statistical analysis
--------------------

We first summarized the patients\' basic information and then analyzed the factors affecting positive tumor markers. Then, the relationship between each group (different scores) and the clinical pathological indicators was tested, and we studied the survival differences among groups. Furthermore, we separately examined the survival differences among different groups with stage II and III CRC.

All data in this study were analyzed by IBM SPSS STATISTICS 22.0 software. Statistical methods mainly used the Pearson chi-square test (minimum theoretical frequency ≥ 5), continuous correction chi-square test (5\>minimum theoretical frequency ≥ 1), Fisher\'s exact probability method (minimum theoretical frequency \< 1) and rank sum test. Survival times, including 3- and 5-year survival rates, were assessed by the Kaplan-Meier method, and the log-rank test was used to compare the differences in survival rates among groups. Cox regression was used to detect the effect of various indicators on the prognosis of stage II and III colorectal cancer. P values were two-sided, with statistically significant differences at p \< 0.05.

Results
=======

A total of 735 patients who underwent curative resection for stage II and III CRC with complete clinical and follow-up data were enrolled in our study. 346 Patients who met our exclusion criteria were excluded (Figure [1](#F1){ref-type="fig"}).

The patients in this study included 446 males (60.7%) and 289 females (39.3%). The median age was 66 years, ranging from 27 to 90. There were 403 patients (54.8%) older than 65, which was slightly higher than those younger than 65 years. A total of 428 patients (58.2%) were in clinicopathological stage II, while stage III accounted for 41.8%. A total of 716 patients had T3 (22.2%) and T4 (75.2%) primary tumors, while T1 and T2 (2.6% plus) tumors were less frequent. N0 was found in 428 patients (58.2%), and 307 patients (41.8%) had lymph node metastasis, with 176 N1 patients (23.9%) and 131 N2 patients (17.8%). In these cases, 461 patients (62.7%) had colon cancer, including 235 with right colon cancer (32.0%) and 226 with left colon cancer (30.7%), and 274 patients (37.3%) had rectal cancer. According to the pathological report, 689 patients (93.7%) had adenocarcinoma and signet ring cell carcinoma, and mucous adenocarcinoma occurred only in 46 cases (6.3%). A total of 435 carcinoma tissues (59.2%) were well or moderately differentiated, while the other 300 tissues (40.8%) were poorly differentiated. According to our data, perineural infiltration in stage II and III CRC tissues was more likely to occur, and 700 cases (95.2%) were observed. Furthermore, lymphatic invasion was found in 439 patients (59.7%), and vascular invasion was caught in 102 patients (13.9%). By the end of our follow-up time, 222 patients (30.2%) had recurrence or metastasis, and 235 patients (32%) had died (Table [1](#T1){ref-type="table"}).

Then, the correlation between preoperative serum tumor markers and clinical and pathological parameters was analyzed. The Chi-square test results showed that the elevation of CEA was associated with clinical stage, T stage (tumor, the depth of primary tumor infiltration), N stage (lymph node, the number and extent of lymph node metastasis), tumor location and lymphatic invasion (all p values \< 0.05; Table [2](#T2){ref-type="table"}). In contrast, there was no significant difference in gender, age, pathology type, differentiation, vascular invasion or perineural invasion (p\>0.05; Table [2](#T2){ref-type="table"}). Our results also found that preoperative serum CA125 expression was significantly different in terms of T stage (T3 and T4), tumor location, pathology type and lymphatic invasion (p \< 0.05; Table [2](#T2){ref-type="table"}). However, there was no significant difference in terms of gender, age, clinical stage, N stage, differentiation, vascular invasion or perineural invasion (p\>0.05; Table [2](#T2){ref-type="table"}). Similar to CEA, the level of CA19-9 had statistical significance with clinical stage, N stage, pathology type, differentiation, lymphatic invasion and vascular invasion (p \< 0.05; Table [2](#T2){ref-type="table"}). However, no significant difference was obtained in terms of gender, age, T stage, tumor location and perineural invasion (p\>0.05; Table [2](#T2){ref-type="table"}). Furthermore, the increase in CA242 was related to clinical stage, N stage, tumor location, pathology type, differentiation and vascular invasion (p \< 0.05; Table [2](#T2){ref-type="table"}), while there was no significant difference in terms of gender, age, T stage, lymphatic invasion or perineural invasion (p\>0.05; Table [2](#T2){ref-type="table"}). In addition, the preoperative elevation of CEA, CA199 and CA242 was associated with metastasis and recurrence as well as poor survival status in stage II and III CRC (p \< 0.05; Table [2](#T2){ref-type="table"}). Interestingly, the increase in CA125 predicted poor survival status (p \< 0.05; Table [2](#T2){ref-type="table"}) rather than metastasis and recurrence (p\>0.05; Table [2](#T2){ref-type="table"}).

Our univariate analysis results indicated that clinical stage, N stage, pathological type, tumor differentiation, lymphatic invasion, vascular invasion and serum tumor markers (CEA, CA125, CA19-9, CA242) were prognostic factors of disease-free survival (DFS) and overall survival (OS). However, gender, age, T stage, tumor location and perineural invasion had no significance for DFS and OS. Multivariate analysis found that CA242 was independent prognostic factor for both DFS (HR=1.641, 95%CI, 1.178- 2.286, p=0.003; Table [3](#T3){ref-type="table"}) and OS (HR=2.003, 95%CI, 1.471- 2.728, p=0.000; Table [3](#T3){ref-type="table"}), and CA125 was independent prognostic factor for OS (HR=1.846, 95%CI, 1.416- 2.406, p=0.000; Table [3](#T3){ref-type="table"}) but not DFS (HR=1.303, 95%CI, 0.983- 1.726, p=0.066; Table [3](#T3){ref-type="table"}).

To verify the weight of each serum tumor marker on the prognosis of stage II and III CRC, we analyzed the differences among these increased tumor markers according to DFS and OS. The results showed no significant difference among these tumor markers between DFS (p=0.053; Figure [2](#F2){ref-type="fig"}A) and OS (p=0.23; Figure [2](#F2){ref-type="fig"}B), which meant that the weight difference of these tumor markers was narrow. Therefore, these 735 patients were scored on a scale of 0 to 4 (five groups) based on the number of preoperative increased tumor markers (if none/anyone/ any two/ any three/all among the 4 markers increased, the score is 0/1/2/3/4 respectively). Then, the association between different scores and clinicopathologic variables was revealed. We found that different scores were closely related to clinical stage, T stage, N stage, tumor location, pathology type, differentiation, lymphatic invasion and vascular invasion (all p values \< 0.05; Table [4](#T4){ref-type="table"}). There was no significant difference in gender, age, T3/T4, or perineural invasion (p\>0.05; Table [4](#T4){ref-type="table"}). In addition, these different scores significantly affected metastasis as well as the recurrence status and survival status (p \< 0.05; Table [4](#T4){ref-type="table"}). To further clarify which groups had differences, we selected the clinicopathologic variables with p values less than 0.05 for a subgroup analysis. As shown in Table [5](#T5){ref-type="table"}, there was a pairwise comparison between different scores and variables (Table [5](#T5){ref-type="table"}).

To assess the effects of different scores on the prognosis of stage II and III CRC, Kaplan-Meier survival curves were performed according to our follow-up data. The results showed that patients with high scores had poor DFS and OS; additionally, the higher the score was, the poorer the survival. The 3-year and 5-year DFS for scores 0-4 ranged from 84.0% and 75.9% to 42.9% and 31.7% (p\<0.001; Figure [3](#F3){ref-type="fig"}A). For OS, the 3-year and 5-year rates for scores 0-4 decreased from 91.0% and 77.9% to 37.8% and 23.6% (p\<0.001; Figure [3](#F3){ref-type="fig"}D). Subgroup analysis showed that the survival results of patients with stage II or III CRC also matched this finding. In stage II, the 3-year and 5-year DFS decreased from 88.6% and 80.4% to 53.8% (score=4) and 55.6% (score=3) (p=0.002; Figure [3](#F3){ref-type="fig"}B). The 3-year and 5-year OS for patients with a score of 0 were 93.3% and 83.4%, respectively, which were much higher than the values for those with a score of 4 (52.7% and 42.2%, respectively, p\<0.001; Figure [3](#F3){ref-type="fig"}E). In stage III, this trend was more pronounced. The 3-year and 5-year DFS ranged from 75.2% and 67.4% to 33.3% and 11.1% (p\<0.001; Figure [3](#F3){ref-type="fig"}C). For OS, the rates obviously decreased from 86.6% and 67.8% to 25.7% and 8.6% (p\<0.001; Figure [3](#F3){ref-type="fig"}F). Mean survival time was also demonstrated for patients with different scores of stage II and III CRC. The overall mean DFS was 85.402 months, and the mean OS was 86.208 months for stage II patients. For stage III patients, the mean DFS was 65.997 months, and the mean OS was 65.769 months. In general, the overall DFS was 77.608 months, and the overall OS was 77.8 months for these 735 patients. Interestingly, we found that stage III patients with low scores had a better prognosis than stage II patients with high scores (Table [6](#T6){ref-type="table"}). To verify whether there was a statistically significant difference between them, we performed a statistical analysis of DFS and OS. The results showed that stage III CRC patients with a score of 0 had a longer DFS and OS than stage II patients with scores of 3 and 4, and there was a statistically significant difference in OS (p \< 0.05; Figure [4](#F4){ref-type="fig"}B) but not in DFS (p\>0.05; Figure [4](#F4){ref-type="fig"}A).

Discussion
==========

Preoperative serum tumor markers have long been used as prognostic indicators of CRC. Recently, the role of serum tumor markers has been underestimated due to more predictive indicators, especially the application of genetic testing. Serum tumor markers have often been used as references for the efficacy of postoperative chemotherapy. CEA is the most important serum tumor marker in the prognosis and therapeutic effect of CRC according to current guidelines[@B16], [@B17]. Nevertheless, other serum tumor markers also have significant implications for the prognosis of CRC. Several studies have found that combined detection of multiple tumor markers can improve the early detection of pancreatic cancer[@B18] and colorectal cancer[@B10].

In our study, 735 patients with stage II and III CRC were enrolled and analyzed based on their clinicopathological and follow-up data. We demonstrated the association between tumor markers and clinicopathological parameters, which was consistent with the findings of a previous study[@B19]. Further, patients were scored according to the number of preoperatively increased tumor markers. We also clarified the relationship between groups with different scores and clinicopathologic variables and confirmed that the higher the score was, the worse the survival. More importantly, we observed that patients with stage II with scores of 3 and 4 had shorter overall survival times than those with stage III with a score of 0, and this difference was statistically significant.

Many studies have focused on serum tumor markers in stages I to III CRC. Jung et al. analyzed 472 CRC patients and found that preoperative CEA was an independent prognostic factor with regard to CSS and DFS, and CA 19-9 also had prognostic value for CSS and DFS[@B20]. Another study that enrolled 237 patients found that CEA predicted OS (HR 2.50, 95% CI 1.17-5.36, P = 0.02) and DFS (HR 1.78, 95% CI 1.02-3.13, P = 0.04)[@B7]. Similar to our study, Gao et al. analyzed the relationship between serum tumor markers (including CEA, CA19-9, CA72-4 and CA125) and clinicopathologic factors and suggested that the combination of multiple preoperative tumor markers could improve the early diagnosis and treatment of CRC[@B21]. Additionally, Ning et al. found that the combined detection of serum tumor markers was useful not only in the diagnosis of CRC but also in gastric cancer[@B22]. A study from Japan and the United States focused on preoperative and postoperative CEA levels, and the results suggested that elevated postoperative CEA (hazard ratio, 2.0; 95% CI, 1.1-3.5) had a shorter RFS than normalized postoperative CEA (HR, 0.77; 95% CI, 0.45-1.30)[@B23]. Another innovative study demonstrated that the preoperative CEA cut-off point should be 2.35 ng/mL in stage I and II colon cancer[@B24]. In recent years, many studies have begun to explore the significance of postoperative tumor markers. A Japanese study suggested that the combination of post-CEA and post-CA 19-9 after R0 resection in stage IV CRC could predict the risk of recurrence[@B25]. Moreover, Araujo RL et al. showed that postoperative CEA ≥ 15 ng/ml strongly indicated recurrence after resection for colorectal liver metastases[@B26]. It can be seen that serum tumor markers are of great value in predicting the prognosis of CRC, and we still need to mine more data and conduct more research to show their value.

Nevertheless, few studies had been involved in the survival of patients with stage II and III CRC who were scored based on an increased number of serum tumor markers. As is known, according to the results of current large clinical trials[@B27], [@B28], there are still many controversial points in the subsequent treatment of stage II and III CRC after curative resection. Our study found that stage III patients with low scores had longer DFS and OS times than stage II patients with high scores, which surprised us. Based on pathological reports, postoperative radiotherapy and chemotherapy may have defective aspects. Should we refer to the preoperative serum tumor markers when we give postoperative chemotherapy to stage II patients? In other words, should all stage III patients require whole-course chemotherapy? At the same time, our research has some shortcomings. This is a single-center retrospective case study with a limited number of cases included. In addition, the few numbers of patients with scores of 4 in the study restricted our study of these patients.

Despite some new findings from our study, it is important to note that tumor markers cannot replace the pathological criteria or the role of imaging examinations in the follow-up of CRC. However, as a supplement, serum tumor markers should be given more attention. We will further explore the significance of preoperative and postoperative tumor markers and use serum tumor markers to detect the metastasis or recurrence of CRC as soon as possible.

In conclusion, preoperative serum tumor markers are related to the prognosis of stage II and III CRC, and the number of increased tumor markers is closely related to the DFS and OS of CRC patients.
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###### 

Patient demographics and clinicopathologic features

  Variables                    Patients (N=735)
  ---------------------------- ------------------
  Gender                       
  Male                         446 (60.7%)
  Female                       289 (39.3%)
  Age, median (Range)          66 (27 to 90)
  \<65                         332 (45.2%)
  ≥65                          403 (54.8%)
  Clinical stage               
  II                           428 (58.2%)
  III                          307 (41.8%)
  T stage                      
  T1+T2                        19 (2.6%)
  T3                           163 (22.2%)
  T4                           553 (75.2%)
  N stage                      
  N0                           428 (58.2%)
  N1                           176 (23.9%)
  N2                           131 (17.9%)
  Tumor location               
  Right colon                  235 (32.0%)
  Left colon                   226 (30.7%)
  Rectum                       274 (37.3%)
  Pathological type            
  Adenocarcinoma               689 (93.7%)
  Mucinous Adenocarcinoma      42 (5.7%)
  Signet ring cell carcinoma   4 (0.6%)
  Degree of differentiation    
  Moderate and well            435 (59.2%)
  Poor                         300 (40.8%)
  Lymphatic invasion           
  Yes                          439 (59.7%)
  No                           296 (40.3%)
  Vascular invasion            
  Yes                          102 (13.9%)
  No                           633 (86.1%)
  Perineural invasion          
  Yes                          700 (95.2%)
  No                           35 (4.8%)
  Metastasis and recurrence    
  Yes                          222 (30.2%)
  No                           513 (69.8%)
  Survival status              
  Alive                        500 (68.0%)
  Dead                         235 (32.0%)

###### 

The association of demographics and clinicopathologic characteristics with different serum tumor markers (\# means the p values compared T3 with T4)

  Variables                 CEA                        CA125                        CA19-9                        CA242         
  ------------------------- ----- ----- ----------- -- ------- ----- ----------- -- -------- ----- ----------- -- ------- ----- -----------
  Gender                                0.380                        0.973                         0.301                        0.234
  Male                      186   260                  143     303                  95       351                  98      348   
  Female                    130   159                  93      196                  71       218                  53      236   
  Age                                   0.478                        0.127                         0.377                        0.132
  \<65                      138   194                  97      235                  70       262                  60      272   
  ≥65                       178   225                  139     264                  96       307                  91      312   
  Clinical stage                        0.000                        0.177                         0.000                        0.003
  II                        159   269                  129     299                  76       352                  72      356   
  III                       157   150                  107     200                  90       217                  79      228   
  T stage                               0.012                        0.095                         0.250                        0.305
  T1+T2                     6     13                   7       12                   2        17                   2       17    
  T3                        55    108   0.005^\#^      41      122   0.033^\#^      33       130   0.358^\#^      29      134   0.280^\#^
  T4                        255   298                  188     365                  131      422                  120     433   
  N stage                               0.001                        0.151                         0.000                        0.003
  N0                        159   269                  129     299                  76       352                  72      356   
  N1                        92    84                   67      109                  45       131                  39      137   
  N2                        65    66                   40      91                   45       86                   40      91    
  Location                              0.006                        0.011                         0.319                        0.008
  Right colon               84    151                  90      145                  55       180                  63      172   
  Left colon                114   112                  75      151                  57       169                  45      181   
  Rectum                    156   118                  71      203                  54       220                  43      231   
  Pathology type                        0.056                        0.018                         0.041                        0.000
  Adenocarcinoma            290   399                  214     475                  150      539                  129     560   
  Other                     26    20                   22      24                   16       30                   22      24    
  Differentiation                       0.447                        0.453                         0.044                        0.004
  Moderate and well         182   253                  135     300                  87       348                  74      361   
  Poor                      134   166                  101     199                  79       221                  77      223   
  Lymphatic invasion                    0.014                        0.006                         0.004                        0.068
  Yes                       205   234                  158     281                  115      324                  100     339   
  No                        111   185                  78      218                  51       245                  51      245   
  Vascular invasion                     0.123                        0.864                         0.000                        0.001
  Yes                       51    51                   32      70                   37       65                   33      69    
  No                        265   368                  204     429                  129      504                  118     515   
  Perineural invasion                   0.157                        0.930                         0.430                        0.438
  Yes                       11    24                   11      24                   6        29                   9       26    
  No                        305   395                  225     475                  160      540                  142     558   
  Metastasis & recurrence               0.001                        0.094                         0.000                        0.000
  Yes                       116   106                  81      141                  71       151                  71      151   
  No                        200   313                  155     358                  95       418                  80      433   
  Survival status                       0.000                        0.000                         0.000                        0.000
  Alive                     193   307                  131     369                  90       410                  67      433   
  Dead                      123   112                  105     130                  76       159                  84      151   

###### 

Univariate and multivariate Cox regression analysis for DFS and OS

  Variables                                      DFS                            OS                     
  ---------------------------------------------- ---------------------- ------- ---------------------- -------
  *Univariate analysis*                                                                                
  Gender (male vs. female)                       1.060 (0.809- 1.390)   0.672   1.082 (0.831- 1.407)   0.559
  Age (\<65 vs. ≥65 )                            0.842 (0.647- 1.095)   0.199   1.104 (0.852- 1.429)   0.454
  Clinical stage (II vs. III)                    2.242 (1.718- 2.926)   0.000   2.412 (1.859- 3.131)   0.000
  T stage                                                                                              
  T1+T2                                          1 (Referent)                   1 (Referent)           
  T3                                             0.599 (0.267- 1.347)   0.215   0.836 (0.354- 1.976)   0.684
  T4                                             1.013 (0.476- 2.156)   0.973   1.404 (0.623- 3.167)   0.413
  N stage                                                                                              
  N0                                             1 (Referent)                   1 (Referent)           
  N1                                             1.611 (1.160- 2.237)   0.004   1.754 (1.276- 2.411)   0.001
  N2                                             3.308 (2.426- 4.510)   0.000   3.513 (2.597- 4.752)   0.000
  Location                                                                                             
  Right colon                                    1 (Referent)                   1 (Referent)           
  Left colon                                     1.233 (0.880- 1.730)   0.224   1.072 (0.775- 1.483)   0.675
  Rectum                                         1.218 (0.881- 1.684)   0.234   1.086 (0.796- 1.482)   0.603
  Pathology type (Adenocarcinoma vs. other)      0.443 (0.292- 0.672)   0.000   0.484 (0.322- 0.727)   0.000
  Differentiation (Moderate and well vs. poor)   1.475 (1.133- 1.919)   0.004   1.547 (1.196- 1.999)   0.001
  Lymphatic invasion (yes vs. no)                1.362 (1.032- 1.797)   0.029   1.383 (1.051- 1.819)   0.020
  Vascular invasion (yes vs. no)                 1.998 (1.444- 2.765)   0.000   1.878 (1.371- 2.573)   0.000
  Perineural invasion (yes vs. no)               1.557 (0.769- 3.155)   0.219   2.162 (0.961- 4.864)   0.062
  CEA (positive vs. negative)                    1.665 (1.279- 2.167)   0.000   1.661 (1.286- 2.146)   0.000
  CA125 (positive vs. negative)                  1.373 (1.045- 1.805)   0.023   1.904 (1.472- 2.463)   0.000
  CA19-9 (positive vs. negative)                 1.851 (1.396- 2.455)   0.000   1.863 (1.417- 2.450)   0.000
  CA242 (positive vs. negative)                  2.343 (1.765- 3.109)   0.000   2.787 (2.132- 3.643)   0.000
                                                                                                       
  *Multivariate analysis*                                                                              
  N stage                                                                                              
  N0                                             1 (Referent)                   1 (Referent)           
  N1                                             1.854 (1.264- 2.719)   0.002   1.997 (1.386- 2.876)   0.000
  N2                                             3.653 (2.442- 5.465)   0.000   4.298 (2.919- 6.328)   0.000
  Pathology type (Adenocarcinoma vs. other)      0.569 (0.362- 0.894)   0.014   0.625 (0.403- 0.970)   0.036
  Differentiation (M and W vs. poor)             1.276 (0.958- 1.699)   0.096   1.309 (0.989- 1.733)   0.060
  Lymphatic invasion (yes vs. no)                1.656 (1.139- 2.407)   0.008   1.802 (1.254- 2.588)   0.001
  Vascular invasion (yes vs. no)                 1.522 (1.086- 2.134)   0.015   1.440 (1.038- 1.999)   0.029
  CEA (positive vs. negative)                    1.282 (0.967- 1.700)   0.084   1.238 (0.942- 1.627)   0.125
  CA125 (positive vs. negative)                  1.303 (0.983- 1.726)   0.066   1.846 (1.416- 2.406)   0.000
  CA19-9 (positive vs. negative)                 1.156 (0.830- 1.609)   0.391   1.113 (0.810- 1.529)   0.510
  CA242 (positive vs. negative)                  1.641 (1.178- 2.286)   0.003   2.003 (1.471- 2.728)   0.000

###### 

The association of demographics and clinicopathologic characteristics with different scores (\# means the p value compared T3 with T4)

  Variables                   0     1     2     3    4    p-value
  --------------------------- ----- ----- ----- ---- ---- -----------
  Gender                                                  0.370
  Male                        155   136   100   33   22   
  Female                      93    91    67    30   8    
  Age                                                     0.184
  \<65                        119   110   67    22   14   
  ≥65                         129   117   100   41   16   
  Stage                                                   0.000
  II                          163   148   75    29   13   
  III                         85    79    92    34   17   
  T stage                                                 0.042
  T1+T2                       8     5     6     0    0    
  T3                          66    54    28    12   3    0.054^\#^
  T4                          174   168   133   51   27   
  N stage                                                 0.000
  N0                          163   148   75    29   13   
  N1                          45    51    52    24   4    
  N2                          40    28    40    10   13   
  Location                                                0.002
  Right colon                 82    68    43    30   12   
  Left colon                  66    64    68    21   7    
  Rectum                      100   95    56    12   11   
  Pathology type                                          0.001
  Adenocarcinoma              239   218   153   56   23   
  Other                       9     9     14    7    7    
  Differentiation                                         0.020
  Moderate and well           152   149   89    29   16   
  Poor                        96    78    78    34   14   
  Lymphatic invasion                                      0.001
  Yes                         131   126   116   44   22   
  No                          177   101   51    19   8    
  Vascular invasion                                       0.020
  Yes                         27    28    24    15   8    
  No                          221   199   143   48   22   
  Perineural invasion                                     0.718
  Yes                         236   216   157   62   29   
  No                          12    11    10    1    1    
  Metastasis and recurrence                               0.000
  Yes                         52    65    59    28   18   
  No                          196   162   108   35   12   
  Survival status                                         0.000
  Alive                       204   157   101   29   9    
  Dead                        44    70    66    34   21   

###### 

Further pairwise comparison of parameters with p values less than 0.05 in the Table [4](#T4){ref-type="table"}

  Variables                   0 vs 1   0 vs 2   0 vs 3   0 vs 4      1 vs 2   1 vs 3   1 vs 4      2 vs 3   2 vs 4      3 vs 4
  --------------------------- -------- -------- -------- -------- -- -------- -------- -------- -- -------- -------- -- --------
  Stage                       0.904    0.000    0.004    0.016       0.000    0.006    0.020       0.879    0.873       0.807
  T stage                     0.585    0.063    0.136    0.021       0.188    0.231    0.052       0.737    0.169       0.419
  N stage                     0.318    0.000    0.002    0.002       0.000    0.017    0.001       0.358    0.041       0.006
  Location                    0.764    0.010    0.006    0.748       0.033    0.003    0.533       0.005    0.139       0.175
  Pathology type              0.848    0.038    0.037    0.000       0.065    0.059    0.000       0.522    0.034       0.218
  Differentiation             0.326    0.105    0.028    0.400       0.013    0.005    0.186       0.326    0.997       0.510
  Lymphatic invasion          0.003    0.000    0.000    0.001       0.005    0.041    0.063       0.955    0.670       0.729
  Vascular invasion           0.622    0.289    0.007    0.030       0.555    0.023    0.065       0.089    0.158       0.765
  Metastasis and recurrence   0.053    0.001    0.000    0.000       0.157    0.017    0.001       0.204    0.011       0.161
  Survival status             0.001    0.000    0.000    0.000       0.073    0.001    0.000       0.049    0.002       0.142

###### 

Means and 95% CI for DFS and OS in patients with stage II and III CRC

  Stage     Score     Mean disease-free survival time(months)   Mean overall survival time(months)                                                
  --------- --------- ----------------------------------------- ------------------------------------ -------- -------- -------- -------- -------- --------
  II        0         90.943                                    2.626                                85.795   96.09    93.883   2.362    89.254   98.513
  1         85.274    3.157                                     79.087                               91.461   84.755   3.063    78.752   90.758   
  2         81.966    4.531                                     73.085                               90.846   83.354   4.143    75.234   91.475   
  3         57.824    6.967                                     44.169                               71.478   61.525   7.105    47.6     75.45    
  4         63        12.325                                    38.843                               87.157   60.116   11.137   38.288   81.945   
  Overall   85.403    1.853                                     81.771                               89.036   86.208   1.754    82.77    89.646   
  III       0         77.497                                    4.579                                68.522   86.472   81.298   4.236    72.995   89.601
  1         67.027    4.919                                     57.385                               76.668   68.136   4.337    59.635   76.636   
  2         60.782    4.692                                     51.586                               69.978   59.778   4.232    51.484   68.073   
  3         46.062    6.206                                     33.898                               58.227   43.123   5.413    32.514   53.732   
  4         28.489    7.276                                     14.228                               42.75    29.319   6.052    17.457   41.181   
  Overall   65.997    2.616                                     60.869                               71.124   65.769   2.407    61.051   70.488   
  Overall   Overall   77.608                                    1.58                                 74.51    80.706   77.8     1.492    74.875   80.725
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